Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease
The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) and vascular dementia (VaD) are intertwined by mixed dementia (MD) harboring varying degrees of AD pathology in combination with cerebrovascular disease. The aim was to assess whether there is a difference in the cerebrospinal fluid (CSF) profile, of selected proteins, between patients with VaD and MD with subcortical vascular disease (SVD), AD, and healthy controls that could contribute in the separation of the groups. The study included 30 controls, 26 SVD patients (9 VaD and 17 MD) and 30 AD patients. The protein panel included total tau (T-tau), hyperphosphorylated tau 181 (P-tau(181)), amyloid β 1-42 (Aβ(1-42)), neurofilament light (NF-L), myelin basic protein (MBP), heart fatty acid binding protein (H-FABP), matrix metalloproteinases (MMP-1, -2, -3, -9, and -10), and tissue inhibitors of metalloproteinases (TIMP-1 and -2). Immunochemical methods were utilized for quantification of the proteins in CSF and data analysis was performed with a multivariate discriminant algorithm. The concentrations of MBP, TIMP-1, P-tau(181), NF-L, T-tau, MMP-9, Aβ(1-42), and MMP-2 contributed the most to the separation between SVD and AD, with a sensitivity of 89% and a specificity of 90% (AUC = 0.92). MBP and NF-L performed the best in discriminating SVD from controls, while T-tau and Aβ(1-42) contributed the most in segregating AD from controls. The CSF biomarkers reflecting AD pathology (T-tau, P-tau(181), and Aβ(1-42)), white matter lesions (NF-L and MBP) and ma…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while increased levels of metaloproteinases MMP-1, MMP-3 and MMP-10 have also been reported in AD [223,224,225,226].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [224]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease
Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., & Perry, G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02653.1997 · Cited by 1,239 · cited 1×
“There are many detailed studies supporting these findings [68–75].”
Barrett, A. J., & Starkey, P. M. (1973) · Biochemical Journal · doi:10.1042/bj1330709 · Cited by 1,062 · cited 1×
“Further complicating the picture is the regulation of the MMPs by TIMPs and that the inhibitors have a biological function of their own [10, 11, 13, 14].”
Metalloproteinases in biology and pathology of the nervous system
Yong, V. W., Power, C., Forsyth, P., & Edwards, D. R. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081571 · Cited by 1,060 · cited 3×
“Mounting evidence indicates that matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) may play an important role in the pathology of neurodegenerative and neuroinflammatory diseases [10–12].”
Tibbling, G., Link, H., & Ohman, S. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517709091496 · Cited by 966
Rosenberg, G. A., Estrada, E. Y., & Dencoff, J. E. (1998) · Stroke · doi:10.1161/01.str.29.10.2189 · Cited by 861
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationHeterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations
Gouw, A. A., Seewann, A., van der Flier, W. M., Barkhof, F., Rozemuller, A. M., Scheltens, P., & Geurts, J. J. G. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.204685 · Cited by 766
Progress in matrix metalloproteinase research
MURPHY, G., & NAGASE, H. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.05.002 · Cited by 759 · cited 2×
“structural proteins such as tight junction proteins and MBP [11, 58, 59].”
Multi- and megavariate data analysis
Eriksson, L. (2006) · Cited by 736
Role of matrix metalloproteinases in delayed cortical responses after stroke
Zhao, B.-Q., Wang, S., Kim, H.-Y., Storrie, H., Rosen, B. R., Mooney, D. J., Wang, X., & Lo, E. H. (2006) · Nature Medicine · doi:10.1038/nm1387 · Cited by 702 · cited 1×
“[20–22].”
Research criteria for subcortical vascular dementia in clinical trials
Erkinjuntti, T., Inzitari, D., Pantoni, L., Wallin, A., Scheltens, P., Rockwood, K., Roman, G. C., Chui, H., & Desmond, D. W. (2000) · Advances in Dementia Research · doi:10.1007/978-3-7091-6781-6_4 · Cited by 631 · cited 1×
“…n = 17) or subcortical VaD ( n = 9) and 30 healthy controls participated in this The diagnosis of dementia was based on the DSM-III-R criteria [31] NINCDS-ADRDA and ICD-10 [32] with regard to Erkinjuntti criteria [33] with regard to SVD, and − 10 with regard to MD (AD with cerebrovascular lesions).”
Self-citationAsahi, M., Asahi, K., Jung, J.-C., del Zoppo, G. J., Fini, M. E., & Lo, E. H. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200012000-00007 · Cited by 610 · cited 1×
“[17–19].”
Matrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594 · cited 2×
“Mounting evidence indicates that matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) may play an important role in the pathology of neurodegenerative and neuroinflammatory diseases [10–12].”
Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice
Friede, R. L., & Samorajski, T. (1970) · The Anatomical Record · doi:10.1002/ar.1091670402 · Cited by 536 · cited 1×
“The notion that tau might reflect degeneration of the grey matter and NF-L degeneration of white matter is supported by the findings that unmyelinated axons are predominantly associated with microtubules and tau, while large caliber myelinated axons outweigh small caliber unmyelinated axons in their neurofilament cont…”
Candelario-Jalil, E., Yang, Y., & Rosenberg, G. A. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.06.025 · Cited by 527
Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjögren, M., Andreasen, N., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 488
Self-citationβ‐Amyloid inhibits integrated mitochondrial respiration and key enzyme activities
Casley, C. S., Canevari, L., Land, J. M., Clark, J. B., & Sharpe, M. A. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00681.x · Cited by 480 · cited 1×
“There are many detailed studies supporting these findings [68–75].”
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
Blennow, K. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.213 · Cited by 477 · cited 1×
“ral (FTD), and Lewy body dementias [5].”
Self-citationZhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F.-F., Xu, H., & Zhang, Y.-W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608856200 · Cited by 436
Dementia after ischemic stroke: A population-based study in Rochester, Minnesota (1960-1984)
Kokmen, E., Whisnant, J. P., O'Fallon, W. M., Chu, C.-P., & Beard, C. M. (1996) · Neurology · doi:10.1212/wnl.46.1.154 · Cited by 434
Gu, Z., Cui, J., Brown, S., Fridman, R., Mobashery, S., Strongin, A. Y., & Lipton, S. A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1563-05.2005 · Cited by 417 · cited 1×
“[17–19].”
Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G., & Love, S. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00132.x · Cited by 381 · cited 1×
“Mounting evidence indicates that matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) may play an important role in the pathology of neurodegenerative and neuroinflammatory diseases [10–12].”
Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380 · cited 1×
“also been shown to be induced by A [24–27] and furthermore MMP−2, −3 and −9 are all able to degrade A in vitro [28, 29].”
Elevated neurofilament levels in neurological diseases
Norgren, N., Rosengren, L., & Stigbrand, T. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03219-0 · Cited by 351
Bu�e, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., Morrison, J. H., & Fillit, H. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00294173 · Cited by 334
Backstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331
Clark, A. W., Krekoski, C. A., Bou, S.-S., Chapman, K. R., & Edwards, D. R. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00859-8 · Cited by 328 · cited 1×
“focal ischemia [60].”
THE EFFECT OF DIFFERENT DIAGNOSTIC CRITERIA ON THE PREVALENCE OF DEMENTIA
Rkinjuntti, T. I. E., Stbye, T. R. Ø., Teenhuis, R. U. S., & Achinski, V. L. H. (1997) · Cited by 315
Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma
Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301 · cited 1×
“The CSF analyses on T-tau [34], phospho-tau181 (P-tau181) [35], and A 1-42 [36] levels were performed by Innogenetics enzymelinked immunosorbent assays (ELISA)(INNOTEST® hTau Ag, INNOTEST® PHOSPHO-TAU(181P), and INNOTEST® -AMYLOID(1–42)), with a slightly modified protocol for A 1-42 [37].”
Self-citationAmyloid β-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis
Keil, U., Bonert, A., Marques, C. A., Scherping, I., Weyermann, J., Strosznajder, J. B., Müller-Spahn, F., Haass, C., Czech, C., Pradier, L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405600200 · Cited by 287
Lee, S.-R., Kim, H.-Y., Rogowska, J., Zhao, B.-Q., Bhide, P., Parent, J. M., & Lo, E. H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4085-05.2006 · Cited by 286 · cited 1×
“[20–22].”
Both total and phosphorylated tau are increased in Alzheimer's disease
Sjogren, M. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.624 · Cited by 253
Self-citationIhara, M., Polvikoski, T. M., Hall, R., Slade, J. Y., Perry, R. H., Oakley, A. E., Englund, E., O’Brien, J. T., Ince, P. G., & Kalaria, R. N. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0635-8 · Cited by 244 · cited 1×
“AD patients, it was proposed that myelin loss, which was less prominent in AD compared to VaD, evolve by different mechanisms such as primary hypoxic damage to oligodendrocytes in VaD whereas secondary to degeneration of axons in AD [52].”
Lee, S.-R., Tsuji, K., Lee, S.-R., & Lo, E. H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4243-03.2004 · Cited by 241 · cited 1×
“[61].”
Pathophysiology of Age-Related Cerebral White Matter Changes
Pantoni, L. (2002) · Cerebrovascular Diseases · doi:10.1159/000049143 · Cited by 219 · cited 1×
“WMLs are frequent pathological hallmarks seen in VaD patients and are in part thought to be caused by small vessel disease [42, 43].”
Omlin, F. X. (1982) · The Journal of Cell Biology · doi:10.1083/jcb.95.1.242 · Cited by 217 · cited 1×
“Moreover, myelin basic protein (MBP) could also serve as a marker of white matter degeneration [7] and has been shown to be more increased in stroke with subcortical infarcts as compared to cortical infarcts [8].”
Multiphasic roles for matrix metalloproteinases after stroke
ROSELL, A., & LO, E. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.12.001 · Cited by 215 · cited 1×
“[20–22].”
Neurofilament protein in cerebrospinal fluid: A marker of white matter changes
Sjögren, M., Blomberg, M., Jonsson, M., Wahlund, L. ‐., Edman, Å., Lind, K., Rosengren, L., Blennow, K., & Wallin, A. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1242 · Cited by 209
Self-citationGardner, J., & Ghorpade, A. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10835 · Cited by 199 · cited 1×
“Further complicating the picture is the regulation of the MMPs by TIMPs and that the inhibitors have a biological function of their own [10, 11, 13, 14].”
β‐Amyloid fragment 25–35 selectively decreases complex IV activity in isolated mitochondria
Canevari, L., Clark, J. B., & Bates, T. E. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01028-5 · Cited by 196
Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium
Harkness, K. A. (2000) · Brain · doi:10.1093/brain/123.4.698 · Cited by 195 · cited 1×
“A induced MMP−9 involvement in BBB disruption has also been demonstrated [27, 76] and the involvement of MMP−9 in the degradation of tight junction proteins, such as ZO−1 [77, 78].”
Marques, C. A., Keil, U., Bonert, A., Steiner, B., Haass, C., Müller, W. E., & Eckert, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212265200 · Cited by 175 · cited 1×
“There are many detailed studies supporting these findings [68–75].”
Chesler, L., Golde, D., Bersch, N., & Johnson, M. (1995) · Blood · doi:10.1182/blood.v86.12.4506.bloodjournal86124506 · Cited by 169
Lorenzl, S., Albers, D. S., LeWitt, P. A., Chirichigno, J. W., Hilgenberg, S. L., Cudkowicz, M. E., & Beal, M. F. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00398-2 · Cited by 164 · cited 1×
“This is in contrast with previous findings [80, 81].”
Deb, S., & Gottschall, P. E. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66041641.x · Cited by 163 · cited 1×
“also been shown to be induced by A [24–27] and furthermore MMP−2, −3 and −9 are all able to degrade A in vitro [28, 29].”
Fujimoto, M., Takagi, Y., Aoki, T., Hayase, M., Marumo, T., Gomi, M., Nishimura, M., Kataoka, H., Hashimoto, N., & Nozaki, K. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.59 · Cited by 158
Adair, J. C., Charlie, J., Dencoff, J. E., Kaye, J. A., Quinn, J. F., Camicioli, R. M., Stetler-Stevenson, W. G., & Rosenberg, G. A. (2004) · Stroke · doi:10.1161/01.str.0000127420.10990.76 · Cited by 141 · cited 2×
“patients compared to AD and controls [23].”
PTEN: A crucial mediator of mitochondria-dependent apoptosis
Zhu, Y., Hoell, P., Ahlemeyer, B., & Krieglstein, J. (2006) · APOPTOSIS · doi:10.1007/s10495-006-3714-5 · Cited by 134
Neurobiochemical Markers of Brain Damage in Cerebrospinal Fluid of Acute Ischemic Stroke Patients
Brouns, R., Vil, B. B. D., Cras, P. P., Surgeloose, D. D., Mariën, P., & Deyn, P. P. D. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.134122 · Cited by 130
Mori, T., Wang, X., Aoki, T., & Lo, E. H. (2002) · Journal of Neurotrauma · doi:10.1089/089771502320914642 · Cited by 129 · cited 1×
“A induced MMP−9 involvement in BBB disruption has also been demonstrated [27, 76] and the involvement of MMP−9 in the degradation of tight junction proteins, such as ZO−1 [77, 78].”
Asahina, M., Yoshiyama, Y., & Hattori, T. (2001) · PubMed · Cited by 129
Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brain
Yoshiyama, Y., Asahina, M., & Hattori, T. (2000) · Acta Neuropathologica · doi:10.1007/pl00007428 · Cited by 128 · cited 1×
“It has been shown that the expression of MMP−3 and MMP−9 are elevated in the human brain and co-localize with amyloid plaques and neurofibrillary tangles [65, 66].”
A novel intracellular role of matrix metalloproteinase‐3 during apoptosis of dopaminergic cells
Choi, D. H., Kim, E., Son, H. J., Joh, T. H., Kim, Y. S., Kim, D., Flint Beal, M., & Hwang, O. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05399.x · Cited by 124 · cited 1×
“Recent evidence has implicated MMP−3 as an intracellular mediator of neuronal apoptosis [64].”
Lee, J., Yin, K., Hsin, I., Chen, S., Fryer, J. D., Holtzman, D. M., Hsu, C. Y., & Xu, J. (2003) · Annals of Neurology · doi:10.1002/ana.10671 · Cited by 115 · cited 1×
“A induced MMP−9 involvement in BBB disruption has also been demonstrated [27, 76] and the involvement of MMP−9 in the degradation of tight junction proteins, such as ZO−1 [77, 78].”
One-Step Enzyme-Linked Immunosorbent Assay (ELISA) for Plasma Fatty Acid-Binding Protein
Wodzig, K. W. H., Pelsers, M. M. A. L., van der Vusse, G. J., Roos, W., & Glatz, J. F. C. (1997) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/000456329703400307 · Cited by 115 · cited 1×
“The H-FABP concentration was assessed using an ELISA from Hycult® Biotech according to manufacturer’s instructions [39].”
A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia
Petzold, A., Keir, G., Warren, J., Fox, N., & Rossor, M. N. (2007) · Neurodegenerative Diseases · doi:10.1159/000101843 · Cited by 112
Cuadrado, E., Rosell, A., Penalba, A., Slevin, M., Alvarez-Sabín, J., Ortega-Aznar, A., & Montaner, J. (2009) · Journal of Proteome Research · doi:10.1021/pr801012x · Cited by 108 · cited 1×
“In another study investigating the MMP profile of infarcted human brain tissue after stroke, it was demonstrated that MMP−1, −2, −3, −8, −9, −10, and −13, in addition to TIMP−1 were upregulated compared to healthy control tissue and that MMP−10 was profoundly increased in neurons [63].”
Aβ accumulation in choroid plexus is associated with mitochondrial-induced apoptosis
Vargas, T., Ugalde, C., Spuch, C., Antequera, D., Morán, M., Martín, M. A., Ferrer, I., Bermejo‐Pareja, F., & Carro, E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.017 · Cited by 104
Stomrud, E., Björkqvist, M., Janciauskiene, S., Minthon, L., & Hansson, O. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt44 · Cited by 103 · cited 1×
“This is in contrast with previous findings [80, 81].”
Decreased myelin lipids in Alzheimer's disease and vascular dementia
Wallin, A., Gottfries, C. G., Karlsson, I., & Svennerholm, L. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb03886.x · Cited by 97 · cited 1×
“[51], and in a recent study on brain tissue from VaD and”
Self-citationMizoguchi, H., Takuma, K., Fukuzaki, E., Ibi, D., Someya, E., Akazawa, K.-H., Alkam, T., Tsunekawa, H., Mouri, A., Noda, Y., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154724 · Cited by 95
Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival
LAMBERT, E., BOUDOT, C., KADRI, Z., SOULA-ROTHHUT, M., SOWA, M.-L., MAYEUX, P., HORNEBECK, W., HAYE, B., & PETITFRERE, E. (2003) · Biochemical Journal · doi:10.1042/bj20030187 · Cited by 94 · cited 1×
“For instance, TIMP−1 has been shown to induce hematopoietic cell survival [15, 16].”
ROCKWOOD, K., MACKNIGHT, C., WENTZEL, C., BLACK, S., BOUCHARD, R., GAUTHIER, S., FELDMAN, H., HOGAN, D., KERTESZ, A., MONTGOMERY, P., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06408.x · Cited by 81 · cited 1×
“are recognized as MD [50].”
Nägga, K., Gottfries, J., Blennow, K., & Marcusson, J. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000066023 · Cited by 71 · cited 1×
“A common denominator of VaD and AD, which could explain the altered amyloid metabolism previously reported in both VaD and AD patients [54], might be cerebral ischemia that has been seen to correlate to amyloid angiopathy [55].”
Self-citationDevelopment of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF
Vanderstichele, H., Blennow, K., D'Heuvaert, N., Buyse, M.-A., Wallin, A., Andreasen, N. C., Seubert, P. A., VOORDE, A. V. D., & Vanmechelen, E. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_110 · Cited by 70
Self-citationChiasserini, D., Parnetti, L., Andreasson, U., Zetterberg, H., Giannandrea, D., Calabresi, P., & Blennow, K. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101293 · Cited by 62 · cited 1×
“However, it is also highly correlated with T-tau in AD [53].”
Self-citationClassification and Subtypes of Vascular Dementia
Wallin, A., Milos, V., Sjögren, M. J. C., Pantoni, L., & Erkinjuntti, T. (2003) · International Psychogeriatrics · doi:10.1017/s1041610203008937 · Cited by 56 · cited 1×
“VaD may involve multiple ischemic lesions, a single strategic lesion or a progressive small vessel disease with demyelination [1–3].”
Self-citationTalamagas, A. A., Efthimiopoulos, S., Tsilibary, E. C., Figueiredo-Pereira, M. E., & Tzinia, A. K. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.016 · Cited by 53
Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment
Bjerke, M., Andreasson, U., Rolstad, S., Nordlund, A., Lind, K., Zetterberg, H., Edman, Å., Blennow, K., & Wallin, A. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000252773 · Cited by 51
Self-citationMlekusch, R., & Humpel, C. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.09.043 · Cited by 49 · cited 1×
“Reduced CSF levels of MMP − 2 MMP − 3 have been found in AD patients with significantly reduced A 1-42 levels, possibly reflect-ing formation [30].”
Acute axonal damage predicts clinical outcome in patients with multiple sclerosis
Lim, E. T., Sellebjerg, F. T., Jensen, C. V., Altmann, D. R., Grant, D., Keir, G., Thompson, E. J., & Giovannoni, G. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1218oa · Cited by 44 · cited 1×
“Moreover, high levels of CSF neurofilament correlate with abnormalities in both MBP and WML in multiple sclerosis [49].”
Hernández‐Guillamon, M., Delgado, P., Ortega, L., Pares, M., Rosell, A., García‐Bonilla, L., Fernández‐Cadenas, I., Borrell‐Pagès, M., Boada, M., & Montaner, J. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22034 · Cited by 39
The Overlap between Alzheimer’s Disease and Vascular Dementia: The Role of White Matter Changes
Wallin, A. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051187 · Cited by 34 · cited 1×
“VaD may involve multiple ischemic lesions, a single strategic lesion or a progressive small vessel disease with demyelination [1–3].”
Self-citationAliyev, A., Seyidova, D., Rzayev, N., Obrenovich, M. E., Lamb, B. T., Chen, S. G., Smith, M. A., Perry, G. L., de la Torre, J. C., & Aliev, G. (2004) · Neurological Research · doi:10.1179/01610425017613 · Cited by 29 · cited 1×
“There are many detailed studies supporting these findings [68–75].”
Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: The Rotterdam Study
Reitz, C., van Rooij, F. J. A., Soares, H. D., de Maat, M. P. M., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.033 · Cited by 22 · cited 1×
“also been shown to be induced by A [24–27] and furthermore MMP−2, −3 and −9 are all able to degrade A in vitro [28, 29].”
Vascular Dementia: The Role of Changes in the Vessels
Ogata, J. (1999) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199912003-00009 · Cited by 18
Matsui, Y., Satoh, K., Mutsukura, K., Watanabe, T., Nishida, N., Matsuda, H., Sugino, M., Shirabe, S., Eguchi, K., & Kataoka, Y. (2010) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-010-9529-5 · Cited by 14 · cited 2×
“Heart fatty acid binding protein (H-FABP) has been proposed as a biomarker reflecting both neuronal degeneration and astrogliosis [9] by providing unique information compared to T-tau.”
Cited by
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Self-citationNeurofilaments and Neurofilament Proteins in Health and Disease
Yuan, A., Rao, M. V., Veeranna, & Nixon, R. A. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018309 · Cited by 731
Human CNS barrier-forming organoids with cerebrospinal fluid production
Pellegrini, L., Bonfio, C., Chadwick, J., Begum, F., Skehel, M., & Lancaster, M. A. (2020) · Science · doi:10.1126/science.aaz5626 · Cited by 461
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Metadata
- Authors
- Bjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U.
- Affiliations
- University of Gothenburg (SE)
- Institute of Neuroscience and physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
- Corresponding author
- Bjerke, Maria
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2011-11-29
- Volume
- 27
- Issue
- 3
- Pages
- 665-676
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1585099387
- Cited by
- 180
- References
- 78
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 18 · 2022: 14 · 2021: 16 · 2020: 17 · 2019: 12 · 2018: 12 · 2017: 14 · 2016: 10 · 2015: 19 · 2014: 13 · 2013: 11 · 2012: 3
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- vascular dementia, Alzheimer's disease
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Myelin Basic Protein, Female, Humans, Male, Middle Aged, Phosphorylation, Dementia, Vascular, Biomarkers, tau Proteins, Neurofilament Proteins, Tissue Inhibitor of Metalloproteinase-1, Matrix Metalloproteinase 9
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.